Cargando…

Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound

Prostate cancer (PCa) is one of the most common cancer types. Early detection of PC offers the best chance of successful treatment. A noninvasive, image-guided therapy mediated by targeted nanoparticles (NPs) has the potential to improve the efficacy and safety of cancer therapies. Herein, we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Junyong, Wu, Yunfang, Chen, Ziqun, Xiao, Linkang, Zhang, Weili, Cao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821565/
https://www.ncbi.nlm.nih.gov/pubmed/36614265
http://dx.doi.org/10.3390/ijms24010825
_version_ 1784865727890587648
author Dai, Junyong
Wu, Yunfang
Chen, Ziqun
Xiao, Linkang
Zhang, Weili
Cao, Yang
author_facet Dai, Junyong
Wu, Yunfang
Chen, Ziqun
Xiao, Linkang
Zhang, Weili
Cao, Yang
author_sort Dai, Junyong
collection PubMed
description Prostate cancer (PCa) is one of the most common cancer types. Early detection of PC offers the best chance of successful treatment. A noninvasive, image-guided therapy mediated by targeted nanoparticles (NPs) has the potential to improve the efficacy and safety of cancer therapies. Herein, we report a sonosensitive nanoparticle modified with anti-PSMA (prostate-specific membrane antigen) antibodies to activate target prostate tumors. These nanoparticles (PFP@IR780@PTX@liposome NPs) were co-loaded with the chemotherapeutic agent docetaxel and the sonosensitizer IR780, as well as phase-changeable perfluorocarbon (PFC) liquids. The liquid–gas phase change could be induced by low-intensity focused ultrasound (LIFU) in vitro. We found that the PFP@IR780@PTX@liposome NPs can specifically accumulate in prostate tumors after LIFU irradiation, as monitored by ultrasound and photoacoustic imaging. Meanwhile, docetaxel was controllably released from the nanoparticles to achieve enhanced chemotherapeutic therapy in vivo. These sonosensitive phase-changeable NPs can visually treat prostate cancers effectively and have a clinical potential.
format Online
Article
Text
id pubmed-9821565
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98215652023-01-07 Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound Dai, Junyong Wu, Yunfang Chen, Ziqun Xiao, Linkang Zhang, Weili Cao, Yang Int J Mol Sci Article Prostate cancer (PCa) is one of the most common cancer types. Early detection of PC offers the best chance of successful treatment. A noninvasive, image-guided therapy mediated by targeted nanoparticles (NPs) has the potential to improve the efficacy and safety of cancer therapies. Herein, we report a sonosensitive nanoparticle modified with anti-PSMA (prostate-specific membrane antigen) antibodies to activate target prostate tumors. These nanoparticles (PFP@IR780@PTX@liposome NPs) were co-loaded with the chemotherapeutic agent docetaxel and the sonosensitizer IR780, as well as phase-changeable perfluorocarbon (PFC) liquids. The liquid–gas phase change could be induced by low-intensity focused ultrasound (LIFU) in vitro. We found that the PFP@IR780@PTX@liposome NPs can specifically accumulate in prostate tumors after LIFU irradiation, as monitored by ultrasound and photoacoustic imaging. Meanwhile, docetaxel was controllably released from the nanoparticles to achieve enhanced chemotherapeutic therapy in vivo. These sonosensitive phase-changeable NPs can visually treat prostate cancers effectively and have a clinical potential. MDPI 2023-01-03 /pmc/articles/PMC9821565/ /pubmed/36614265 http://dx.doi.org/10.3390/ijms24010825 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dai, Junyong
Wu, Yunfang
Chen, Ziqun
Xiao, Linkang
Zhang, Weili
Cao, Yang
Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound
title Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound
title_full Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound
title_fullStr Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound
title_full_unstemmed Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound
title_short Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound
title_sort sonosensitive phase-changeable nanoparticle mediated enhanced chemotherapy in prostate cancer by low-intensity focused ultrasound
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821565/
https://www.ncbi.nlm.nih.gov/pubmed/36614265
http://dx.doi.org/10.3390/ijms24010825
work_keys_str_mv AT daijunyong sonosensitivephasechangeablenanoparticlemediatedenhancedchemotherapyinprostatecancerbylowintensityfocusedultrasound
AT wuyunfang sonosensitivephasechangeablenanoparticlemediatedenhancedchemotherapyinprostatecancerbylowintensityfocusedultrasound
AT chenziqun sonosensitivephasechangeablenanoparticlemediatedenhancedchemotherapyinprostatecancerbylowintensityfocusedultrasound
AT xiaolinkang sonosensitivephasechangeablenanoparticlemediatedenhancedchemotherapyinprostatecancerbylowintensityfocusedultrasound
AT zhangweili sonosensitivephasechangeablenanoparticlemediatedenhancedchemotherapyinprostatecancerbylowintensityfocusedultrasound
AT caoyang sonosensitivephasechangeablenanoparticlemediatedenhancedchemotherapyinprostatecancerbylowintensityfocusedultrasound